A drug company in Japan plans to buy a Texas company for $2 billion. The Texas company is IntraBio. It is based in Austin. Its main drug is called Aqneursa. The drug is approved for symptoms of two rare diseases. Both harm the brain and nerves.
The buyer is Shionogi. It is based in Osaka, Japan. It announced the deal on Monday, October 5. Its board approved the plan that day. Both sides signed the same day.
Shionogi will pay $2 billion up front to IntraBio's owners. IntraBio will join Shionogi Inc. That is the company's U.S. arm in New Jersey.
The sellers include people, trusts and companies. Shionogi says their names will stay private. The sellers asked for that.
The deal is not final. Shionogi plans to close it in November or December. First, it must clear waiting periods set by competition laws. It also needs the OK from regulators.
Why does it matter? Shionogi says it is the first and only drug approved for ataxia in people with A-T. Ataxia means trouble with balance and movement. A-T is short for ataxia-telangiectasia. Shionogi says A-T is rare and runs in families. It gets worse over time. It starts in early childhood.
A-T harms movement, balance, speech, and eye movements. It can also make it hard to fight off germs. Shionogi says people with A-T do not live as long.
The FDA approved it for A-T on September 18, 2026. The deal came weeks later.
The FDA first approved the drug in September 2024. That was for another rare disease. It is called Niemann-Pick disease type C, or NPC. Shionogi says NPC runs in families. Fats and cholesterol build up in cells. They collect in the brain and other organs. Shionogi says NPC affects about one in 100,000 births. Europe approved the drug for NPC in January.
Does it work? IntraBio ran a trial for A-T. It had 73 patients, ages 4 to 50. The FDA says patients on the drug scored better than those on a placebo. A placebo is a dose with no medicine. The score tracked walking, balance and speech. The company says no one had a serious side effect linked to the drug.
The drug's label says it is not known exactly how the drug works.
IntraBio started in 2015. Its sales in 2025 were about $68 million, Shionogi says.
Shionogi wants to grow in rare diseases. Earlier this year, it bought the global rights to Radicava. That is a drug for ALS. ALS is a disease that damages nerves and muscles.
Isao Teshirogi is the chief executive. He said the deal shows a "solid commitment to building a leading global rare disease business."
Nathan McCutcheon runs Shionogi Inc. He said the deal would bring the first and only A-T drug to people who have waited years.
Shionogi is still studying how the deal will change its money results for the year ending March 2027.
The drug is already for sale in the U.S., Shionogi says. Shionogi's announcement does not say what the deal means for price or supply.